Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wil.

Business Wire • Oct 8, 2026

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe's in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca's next-generation oral selective estrogen.

Business Wire • Oct 8, 2026

Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250

Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.

FXEmpire • Oct 5, 2026

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients wi.

Business Wire • Oct 5, 2026

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

ETF Trends • Sep 30, 2026

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

Market Watch • Sep 23, 2026

AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.

Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.

Investors Business Daily • Sep 21, 2026

Guardant Health Nears Buy Point As Sales Outlook Brightens

Guardant Health provides services across the cancer continuum. Shares are near a buy point of 176.58 after a breakout.

Investors Business Daily • Sep 16, 2026

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Guardant Health's Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states. The latest policy update from Shield marks a rapid growth in commercial adopt.

Business Wire • Sep 14, 2026